 | • レポートコード：MRC2303G093 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、121ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療機器 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書によると、世界のアテレクトミー装置市場規模が、予測期間中（2022年-2027年）CAGR 6.03％で増加すると推測されています。本書では、アテレクトミー装置の世界市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（一方向性、オービタル、光剥離（レーザー）、回転式）分析、用途別（末梢血管、循環器、神経血管）分析、エンドユーザー別（病院・手術センター、外来診療センター、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、Abbott Laboratories、B. Braun SE、Boston Scientific Corporation、Becton, Dickinson and Company、Cardinal Health Inc.、Koninklijke Philips NV、Medtronicなどが含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のアテレクトミー装置市場規模：製品別 - 一方向性アテレクトミー装置の市場規模 - オービタルアテレクトミー装置の市場規模 - 光剥離（レーザー）アテレクトミー装置の市場規模 - 回転式アテレクトミー装置の市場規模 ・世界のアテレクトミー装置市場規模：用途別 - 末梢血管における市場規模 - 循環器における市場規模 - 神経血管における市場規模 ・世界のアテレクトミー装置市場規模：エンドユーザー別 - 病院・手術センターにおける市場規模 - 外来診療センターにおける市場規模 - その他エンドユーザーにおける市場規模 ・世界のアテレクトミー装置市場規模：地域別 - 北米のアテレクトミー装置市場規模 アメリカのアテレクトミー装置市場規模 カナダのアテレクトミー装置市場規模 メキシコのアテレクトミー装置市場規模 … - ヨーロッパのアテレクトミー装置市場規模 ドイツのアテレクトミー装置市場規模 イギリスのアテレクトミー装置市場規模 フランスのアテレクトミー装置市場規模 … - アジア太平洋のアテレクトミー装置市場規模 中国のアテレクトミー装置市場規模 日本のアテレクトミー装置市場規模 インドのアテレクトミー装置市場規模 … - 南米/中東のアテレクトミー装置市場規模 ブラジルのアテレクトミー装置市場規模 アルゼンチンのアテレクトミー装置市場規模 サウジアラビアのアテレクトミー装置市場規模 ・競争状況 ・市場機会・将来動向 |
The atherectomy devices market is expected to record a CAGR of about 6.03% during the forecast period 2022-2027.
Like many other markets, the market was impacted by the COVID-19 pandemic. Various cardiovascular procedures and non-essential treatments were postponed. In March 2022, a research study was published in the Annals of Thoracic Surgery, which analyzed 717,103 adult cardiac surgery patients and more than 20 million COVID-19 patients stated that there was a 52.7% reduction in adult cardiac surgery volume and a 65.5% reduction in elective cases. The Mid-Atlantic region was most affected by the first COVID-19 surge, with a 69.7% reduction in overall case volume and an 80.0% reduction in elective cases. In the Mid-Atlantic and New England regions, the observed-to-expected mortality for isolated coronary bypass increased as much as 1.48 times (148% increase) pre-COVID rates. After the first COVID-19 surge, nationwide cardiac surgical case volumes did not return to baseline, indicating a COVID-19-associated deficit in cardiac surgery patients. Atherectomy is a procedure used to clear out clogged heart arteries. The cardiac surgeries would also include atherectomy surgeries. Hence, the market was affected across the globe. Hence, with the easing of COVID-19 restrictions, worldwide, the market gained traction and is expected to bounce back to its full potential over the years.
The market for atherectomy devices is majorly driven by the increasing preference for minimally invasive surgeries. Research studies about the expansion of minimally invasive surgeries are another factor that drives the market growth. In October 2021, a research study was published in Elsevier Journal, stating that continuous progress in percutaneous coronary intervention (PCI) has inspired surgeons to reduce the invasiveness of surgical revascularization techniques, resulting in the development of minimally invasive cardiac surgery (MICS) procedures, which have widely expanded over the past couple of decades. The main goals of MICS are to avert any form of sternotomy, reduce postoperative blood product transfusion, shorten ventilation times, reduce intensive care and hospital stays, diminish postoperative pain, and accelerate the return to normal activities. Hence, due to such advantages of MICS, there will be growth in the adoption of such surgeries which would increase the market growth.
Additionally, continuous product development and commercialization are expected to propel the growth of the market. In November 2021, Royal Philips launched peripheral and coronary artery applications, including the Nexcimerlaser system in Orlando, United States. The new Philips Laser System – Nexcimer– offers plug-and-play simplicity for coronary and peripheral atherectomy and lead extraction procedures. It is the only system compatible with catheters with Level I clinical data for ISR atherectomy and that can also support lead extraction procedures (the removal of pacemaker or defibrillator leads around the heart).
In the current trend of healthcare, reimbursement, and coverage reform, payer and provider consolidation for escalating healthcare costs are essential for patients and their caregivers. Reimbursement and coverage reform enhances the chances of opting for the treatment if it is covered. Hence, increasing reimbursement would increase the market growth in the upcoming period. In 2022, the Centers for Medicare and Medicaid Services (CMS), has increased reimbursement for peripheral intravascular lithotripsy (IVL) procedures. Procedure including revascularization, endovascular, open or percutaneous, lower extremity arteries, except tibial/peroneal; with intravascular lithotripsy, includes angioplasty within the same vessel (s) (CPT code: C9764) will receive USD 10,258. Similarly, a procedure including revascularization, endovascular, open or percutaneous, lower extremity arteries, except tibial/peroneal; with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessels, (CPT code: C9765) will receive USD 16,402. Furthermore, processes including revascularization, endovascular, open or percutaneous, lower extremity arteries), except tibial/peroneal; with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, including angioplasty within the same vessels, when performed (CPT code: C9767) will receive USD 16,402. Thus, all the above-mentioned factors are expected to boost the market over the forecast period.
However, the stringent regulatory scenarios may restrain the market growth over the forecast period.
Atherectomy Devices Market Trends
Directional Atherectomy Segment Holds a Significant Market Share in the Studied Market Over the Forecast Period
The directional atherectomy segment of the market is expected to witness significant growth in the forecast period over other products as it offers certain advantages such as low treatment cost, improved efficiency, etc. The increasing adoption of minimally invasive atherectomy procedures may boost the demand for atherectomy devices. According to a research study published by Krishna J. Rocha-Singh et. al., in June 2021, plaque removal with directional atherectomy (DA) before drug-coated balloon (DCB) angioplasty is a safe and effective treatment technique with a low provisional stent rate in patients with symptomatic severely calcified femoropopliteal artery disease. Thus, research studies like these are further expected to promote the usage of DA systems which is anticipated to fuel growth in the studied segment.
The strategic initiatives taken by key market players such as product launches, mergers and acquisitions, and partnerships are also expected to contribute to market growth. For instance, in August 2021, Medtronic submitted an application to the USFDA for the approval of the TurboHawk Plus Directional Atherectomy System, an updated version of its older and largely phased-out atherectomy device. This device will facilitate increased atherectomy procedures during Peripheral Arterial Disease (PAD) interventions. Additionally, in November 2021, Avinger Inc. received 510(k) approval from the United States FDA for the Pantherisimage-guided atherectomy system’s new clinical indication. This clearance allows the company to directly market Pantheris forthe treatment of in-stent restenosis (ISR) in the lower extremity arteries.
Therefore, overall, with the growing number of surgeries, and product innovation, the directional atherectomy systems segment is expected to grow during the forecast period of the study.
North America Holds a Significant Share in the Market and Expected to do Same during the Forecast Period
North America is expected to hold a significant share of the market. Factors such as increasing availability of reimbursements for atherectomy systems, adoption of atherectomy systems among medical professionals, the large patient population of peripheral and coronary artery diseases, and an increasing number of clinical trials (that aim to evaluate the therapeutic efficacy of atherectomy systems in specific disease treatment) are driving the growth of the North American atherectomy devices market.
According to the February 2022 update of the CDC, in the United States, heart diseases are the leading cause of death irrespective of gender, race, or ethnicity and the most common type of heart disease is coronary heart disease (CHD) or coronary artery disease in which coronary arteries become too narrow or cholesterol blockages develop in the walls, leading to stroke or heart attack. Thus, due to the rising prevalence of heart diseases, the demand for atherectomy procedures is expected to increase in the region which is anticipated to fuel growth in the studied market over the forecast period.
A suitable reimbursement scenario and a high number of FDA-approved devices are the key reasons for this dominance. For instance, in October 2021, BD (Becton, Dickinson and Company) announced it has received 510(k) clearance for expanded indications from the U.S. FDA for the Rotarex Atherectomy System. Additionally, in November 2021, Royal Philips announced the North American debut of new peripheral and coronary artery applications, including the IntraSight Mobile system and the Nexcimer laser system.
Thus, all above mentioned factors expected to boost the market in the region over the forecast period.
Atherectomy Devices Market Competitor Analysis
The atherectomy devices market is moderately competitive, with the presence of many global players. For instance, Abbott Laboratories, B. Braun SE, Boston Scientific, CR Bard, Cardinal Health Inc., Koninklijke Philips NV, Medtronic PLC, Terumo Corporation, etc., are offering their products across the globe.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Continuous Product Development and Commercialization
4.2.2 Favourable Medical Reimbursement Scenario in Mature Markets
4.2.3 Growing Demand for Minimally Invasive Surgical Procedures
4.3 Market Restraints
4.3.1 Stringent Regulatory Scenario
4.3.2 Lack of Well-trained Surgeons
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD Million)
5.1 By Product
5.1.1 Directional Atherectomy Systems
5.1.2 Orbital Atherectomy Systems
5.1.3 Photo-ablative (Laser) Atherectomy Systems
5.1.4 Rotational Atherectomy Systems
5.2 By Application
5.2.1 Peripheral Vascular Applications
5.2.2 Cardiovascular Applications
5.2.3 Neurovascular Applications
5.3 By End User
5.3.1 Hospitals and Surgical Centers
5.3.2 Ambulatory Care Centers
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 B. Braun SE
6.1.3 Boston Scientific Corporation
6.1.4 Becton, Dickinson and Company
6.1.5 Cardinal Health Inc.
6.1.6 Koninklijke Philips NV
6.1.7 Medtronic
6.1.8 RA Medical Systems
6.1.9 Terumo Corporation
6.1.10 Cardiovascular Systems Inc.
6.1.11 Biomerics LLC
6.1.12 AngioDynamics Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS